RNA Supply Chain Resources

1. Reducing Lead Time, Delivering >99.5% OTIF 1/23/2024

   Explore the stocking solution offered to a mid-sized CDMO in need of a high volume of safety stock inventory to support their customer portfolio growth.

2. Where Can Novel Non-Viral Polymeric Delivery Agents Take Us? 1/18/2023

   Explore ongoing work to harness different types of HDR templates in order to build cutting-edge systems with the potential to enable point-of-care cell and gene therapy manufacture.

3. Eliminating Antibiotic Resistance Gene Transfer Risks In CGTs 8/14/2023

   Learn about the drawbacks of antibiotic resistance that can cause side effects in patients and how an antibiotic-free approach can ease the burden of regulatory compliance and accelerate development.

4. A Novel RNA Lipid Nanoparticle Platform: Gene-Edited CAR T Cells For Off-The-Shelf Cancer Therapy 4/14/2022

   We report on the use of a novel lipid nanoparticle (LNP) reagent in a validated protocol to achieve successful complex gene editing in primary T cells with high efficiency while maintaining high cell viability.

5. Transitioning From Using RUO To cGMP Chemicals For Clinical Trials 10/17/2023

   Learn about the common challenges and risks associated with accelerating your molecule's timeline from lab to clinic, along with important supply chain considerations for emerging biopharma companies.

6. The Role Of CRISPR Cas9 Plasmids In Gene-Editing 12/12/2023

   Plasmids are crucial for CRISPR-Cas9 gene-editing technology, and their role in CRISPR is expected to evolve with ongoing research.

7. Understanding CRISPR Clinical Trials: Your Questions Answered 3/15/2023

   CRISPR technology is revolutionizing cell and gene therapies, but how do CRISPR clinical trials work? Follow this explanation of CRISPR therapies from the discovery phase to FDA approval.

8. Key Challenges for CRISPR In Clinical Development 2/28/2023

   Learn how to approach CRISPR cell and gene therapy development challenges, such as regulatory hurdles, ensuring consistency, finding qualified and experienced staff, and obtaining GMP-Grade reagents.

9. Demystifying CRISPR gRNA Chemical Modifications 10/28/2024

   Chemical modifications on CRISPR gRNAs enhance stability, editing efficiency, and reduce immune responses, enabling in vivo applications and clinical success.

10. Pre-Banking And Avoiding Manufacturing Challenges For GMP Plasmids Containing Unstable Sequence Regions 4/21/2021

    Ensuring consistent replication and proper retention of plasmid DNA sequence is vital to the economics and efficiency in generating starting materials used for production of AAV delivered gene therapy and mRNA vaccines and therapeutics.